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a  b  s  t  r  a  c  t
Background  and  purpose:  Percutaneous  coronary  intervention  (PCI)  with  a drug-eluting  stent  (DES)  is  one
of the  standard  treatments  for  patients  with  stable  angina  pectoris  (AP).  In  spite  of  a notable  effect  in
preventing  restenosis  after  PCI, DES  cannot  improve  the  mortality  of patients  compared  to  a  bare-metal
stent  (BMS).  On the  other  hand,  periprocedural  myocardial  injury  (PMI)  is related  to  poor  prognosis  in
patients undergoing  PCI.  We  compared  DES  to BMS  in  the  incidence  of  PMI  in  patients  with  stable  AP.
Methods  and  subjects:  We  enrolled  265  consecutive  patients  with  AP  undergoing  successful  stent  implan-
tation.  A  blood  sample  was  obtained  from  all patients  immediately  before  and  24 h  after  PCI.  PMI was
deﬁned  as  an increase  in creatine  kinase-myocardial  band  isozyme  fraction  (CK-MB)  greater  than  the
upper  limit  of  reference  range  24 h  after  PCI.  During  the  study  period,  sirolimus-  and  paclitaxel-eluting
stents  were  used  as  DES.  The  strategy  of  PCI  including  the  type  of stent  to implant  was  left  to  the  discretion
of  the operator.
Results:  Patients  were  divided  into  two  groups  (DES group,  n  =  136  and BMS group,  n  = 129).  The  incidence
of  PMI  was  signiﬁcantly  higher  in the  DES  group  than  in  the  BMS  group  (24%  vs.  12%,  p  = 0.015).  Use  of  DES
remained  an  independent  predictor  of  PMI  on  multivariate  logistic  regression  analysis  after  adjustment
for  confounding  factors  (odds  ratio  2.20,  95%  CI, 1.07–4.51,  p =  0.032).
Conclusions:  Implantation  of  the  ﬁrst-generation  DES  including  sirolimus-  and  paclitaxel-eluting  stents
was associated  with  a higher  incidence  of PMI  in  patients  with  AP  compared  to BMS.
© 2012  Japanese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.ntroduction
Percutaneous coronary intervention (PCI) in patients with
ngina pectoris (AP) is a well-established treatment. However,
estenosis after PCI remains a clinical limitation, because it atten-
ates the quality of life and may  even increase the mortality
f patients [1,2]. In such situations, drug-eluting stents (DESs)
ave dramatically suppressed neointimal hyperplasia and even-
ually reduced the risk of restenosis and the necessity of repeat
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[3–5]. Thus, DESs have been widely used in PCI. Unfortunately, the
use of DES is reportedly equivalent to BMS  in terms of long-term
survival [6–8].
On the other hand, procedural-related complications such as
ﬂow-limiting dissection, branch occlusion, thrombus formation,
no-reﬂow, and macroscopic embolization resulting in myocardial
damage also remain clinical problems in PCI. Moreover, peripro-
cedural myocardial injury (PMI) detected even after apparently
non-complicated procedures is associated with future cardiovas-
cular events [9–12]. Until now, there have been limited reports
on whether or not DES use is related to a higher incidence of
PMI. Thus, the aim of this study was to compare implantation
of DES to that of BMS  in the incidence of PMI  in patients with
stable AP.
vier Ltd. All rights reserved.










Age (y) 68 ± 10 67 ± 10 69 ± 10 0.063
Male 213 (80) 110 (81) 103 (80) 0.878
Body  mass index (kg/m2) 23.7 ± 3.7 24.3 ± 3.6 23.1 ± 3.8 0.012
Clinical history
Hypertension 201 (76) 106 (78) 95 (74) 0.439
Diabetes 131 (49) 75 (55) 56 (43) 0.065
Current smoker 73 (28) 32 (24) 41 (32) 0.086
Previous myocardial infarction 60 (23) 36 (26) 24 (19) 0.083
Multiple vessel disease 98 (37) 66 (49) 32 (25) <0.001
Familial history of coronary heart disease 43 (16) 23 (17) 20 (16) 0.868
CK-MB before procedure (IU/l) 12.7 ± 6.7 13.3 ± 6.6 12.2 ± 6.7 0.168
CK-MB 24 h after procedure (IU/l) 18.2 ± 22.9 21.0 ± 23.6 15.4 ± 21.8 0.045
Total  cholesterol (mg/dl) 176.7 ± 35.0 174.2 ± 33.4 179.4 ± 36.6 0.225
LDL-C (mg/dl) 103.2 ± 31.1 99.0 ± 27.6 107.7 ± 34.0 0.023
HDL-C (mg/dl) 46.1 ± 12.9 46.6 ± 12.1 45.5 ± 13.6 0.488
Triglyceride (mg/dl) 139.1 ± 72.6 141.2 ± 76.1 136.9 ± 69.0 0.630
Hemoglobin A1c (%) 6.2 ± 1.0 6.1 ± 1.0 6.2 ± 1.0 0.711
High-sensitivity C-reactive protein (mg/l) 4.8 ± 12.0 3.6 ± 10.4 6.2 ± 13.4 0.076
Left  ventricular ejection fractiona (%) 61 ± 12 61 ± 13 62 ± 11 0.541
Medication
Aspirin 265 (100) 136 (100) 129 (100)
Thienopyridine drug 265 (100) 136 (100) 129 (100)
ACE-I  and/or ARB 154 (58) 88 (65) 66 (51) 0.017
Calcium channel blockers 117 (44) 65 (48) 52 (40) 0.265
Beta-blockers 72 (27) 40 (29) 32 (25) 0.411
Nitrates 53 (20) 31 (23) 22 (17) 0.283
Statins 265 (100) 136 (100) 129 (100)
Insulin  19 (7) 12 (9) 7 (5) 0.345
Oral  diabetes medications 77 (29) 44 (32) 33 (26) 0.110




























Aial  injury; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipopr
eceptor  blockers.
a Left ventricular ejection fraction was measured by echocardiography.
aterials and methods
tudy population
We  enrolled a total of 265 consecutive stable AP patients with
ocumented ischemia between September 2008 and April 2010 at
agoya University Hospital. The inclusion criteria of the study were
atients undergoing elective PCI with angiographically successful
tent implantation for de novo coronary artery lesions except those
ocated at left main trunk. Procedural success was  deﬁned as a ﬁnal
ngiographic residual stenosis of <30% by quantitative coronary
ngiography (QCA) without ﬂow-limiting dissection or occlusion
f the large branch (>1 mm)  or no-ﬂow/slow-reﬂow phenomenon
uring a procedure, and a resulting Thrombolysis in Myocardial
nfarction (TIMI) grade of 3 [13]. Exclusion criteria consisted of
atients with chronic total occlusion, angioplasty with atherec-
omy, abnormal creatine kinase-myocardial band isozyme fraction
CK-MB) value prior to PCI, and/or contraindication to aspirin,
hienopyridine, or statin treatment. The study protocol and chart
eviews were approved by the institutional ethics committee. Writ-
en informed consent was given by all patients prior to procedures.
uantitative coronary angiography and PCI procedure
All patients received treatment with oral aspirin (100 mg/day)
nd thienopyridine drug, and any statins at least two weeks prior
o PCI. Heparin (10,000 IU) was administered intravenously imme-
iately prior to the procedure. Coronary angiograms for QCA were
btained immediately prior to PCI, following an intracoronary infu-
ion of 2.5 mg  isosorbide dinitrate. The projection showing the
aximal degree of stenosis (worst view) was selected for QCA.
nalysis of QCA was performed using a contour detection minimumcholesterol; ACE-I, angiotensin converting enzyme inhibitors; ARB, angiotensin II
cost algorithm (QCA-CMS Version 3.0, MEDIS, Leiden, Netherlands).
Lesion types were divided according to the American Heart Associ-
ation/American College of Cardiology classiﬁcation, and a complex
lesion was  deﬁned as lesion type B2 or C [14]. PCIs were performed
through the femoral or radial artery according to the standard tech-
niques by experienced cardiologists. The strategy of PCI including
type of stent to implant was left to the discretion of the oper-
ator. In our institution, a sirolimus- or paclitaxel-eluting stent
(Cypher, Cordis Corp., Johnson & Johnson, Warren, NJ, USA  and
TAXUS, Express2 or Liberte; Boston Scientiﬁc, Natick, MA,  USA,
respectively) were adopted as DES during the study period. Platelet
glycoprotein IIb/IIIa receptor inhibitors were not used because they
were not available in Japan.
Evaluation of plasma markers
A blood sample was obtained from the atrial sheath just before
and from the peripheral vein 24 h after PCI. CK-MB was measured
using a commercially available immunoinhibition assay kit. The
upper reference limit for CK-MB was 25 IU/l which represented
the 99th percentile of values for reference control groups. PMI  was
deﬁned as an increase in CK-MB greater than the upper limit of
the reference range (ULN) 24 h after PCI, as previously described
[15,16]. The data of various lipid, glucose, and inﬂammatory proﬁles
were also measured immediately before PCI.
Statistical analysisPASW ver. 18 (SPSS, Chicago, IL, USA) was used for all statistical
analyses. Continuous variables were presented as mean ± standard
deviations, and differences between the two  groups were evalu-
ated by the Student unpaired t-test or the Mann–Whitney U-test
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Table  2
The incidence of periprocedural myocardial injury.
Alln = 265 DESn = 136 BMSn = 129 p
CK-MB > 3× ULN 4 (2) 3 (2) 1 (1) 0.623































Fig. 1. Incidence of periprocedural myocardial injury (PMI). In patients treated with
drug-eluting stents (DESs) the incidence of PMI  was 24%, against 12% in patients




qalues are numbers (%). DES, drug-eluting stent; BMS, bare-metal stent; CK-MB,
reatine kinase-myocardial band isozyme fraction; ULN, upper limit of the reference
ange.
f their distribution was abnormal. Categorical variables were pre-
ented as numbers (percentages), and comparisons across the two
roups were performed by the chi-square test or Fisher exact test.
e  performed univariate logistic regression analyses to evaluate
he relationship between PMI  and other confounders. And then,
ultivariate logistic regression analysis was conducted to adjust for
hese variables with p-value <0.2 at univariate logistic regression
nalysis and multiple vessel disease, lesion length, and reference
essel diameter which might affect the incidence of PMI. A vari-
ble with two tailed p-value <0.05 was considered as statistically
igniﬁcant.
esults
Patients were divided into two groups (DES group, n = 136 and
MS  group, n = 129). Table 1 shows the clinical characteristics of
oth groups. Body mass index was signiﬁcantly higher in the DES
roup than in the BMS  group (24.3 ± 3.6 kg/m2 vs. 23.1 ± 3.8 kg/m2,
 = 0.012). The rate of multi-vessel disease was signiﬁcantly higher
n the DES group than the BMS  group (49% vs. 25%, p < 0.001).
igniﬁcantly higher CK-MB levels 24 h after PCI were obtained in
he DES group compared to the BMS  group (21.0 ± 23.6 IU/l vs.
5.4 ± 21.8 IU/l, p = 0.045). The incidence of PMI  was signiﬁcantly
igher in the DES group than in the BMS  group (24% vs. 12%,
 = 0.015) (Fig. 1). However, when PMI  was deﬁned as an increase in
K-MB three times greater than the ULN, the statistical signiﬁcance
isappeared [3 (2%) vs. 1 (1%), p = 0.623]. Furthermore, no patients
xperienced PMI, when it was deﬁned as an increase in CK-MB
ve times greater than the ULN (Table 2). Low-density lipoprotein
holesterol levels were signiﬁcantly lower in the DES group than
able 3




Left anterior descending artery 121 (46) 
Left  circumﬂex artery 59 (22) 
Right  coronary artery 85 (32) 
Complex lesion (type B2/Ca) 114 (43) 
QCA  pre-procedure
Minimum lumen diameter (mm) 0.68 ± 0.37 
Reference vessel diameter (mm)  2.6 ± 0.59 
Diameter stenosis (%) 73 ± 13 
Lesion length (mm)  13.9 ± 4.8 
QCA  post-procedure
Minimum lumen diameter (mm)  2.6 ± 0.50 
Reference vessel diameter (mm)  2.9 ± 0.51 
Diameter stenosis (%) 10.2 ± 6.6 
Lesion length (mm)  18.1 ± 6.7 
PCI  procedure
Direct stenting 31 (12) 
Number of stents 1.3 ± 0.46 
Stent  size (ϕ, mm)  3.0 ± 0.45 
Total  stent length (mm)  20.0 ± 10.5 
Maximum inﬂation pressure (atm) 15.1 ± 3.5 
Total  balloon inﬂation time (s) 119.2 ± 22.5 
alues are mean ± SD or number (%).
a Lesion type was classiﬁed according to American Heart Association/American Colle
uantitative coronary angiography; PCI, percutaneous coronary intervention.deﬁned as an increase in creatine kinase-myocardial band isozyme fraction greater
than the upper limit of the reference range.
the BMS  group (99.0 ± 27.6 mg/dl vs. 107.7 ± 34.0 mg/dl, p = 0.023).
Patients in the DES group signiﬁcantly more frequently took
angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin
II receptor blockers (ARB) (65% vs. 51%, p = 0.017) than those in the
BMS  group. Table 3 provides the data for angiograms and PCI pro-
cedure. DES were more frequently implanted in the left circumﬂex
artery and less frequently implanted in the right coronary artery
than BMS  (32% vs. 12%, p < 0.001 and 24% vs. 41%, p < 0.001). In
addition, DESs were more frequently used to treat complex lesions
than BMS  (54% vs. 31%, p < 0.001). In the DES group, patients had
signiﬁcantly smaller vessels and had longer lesions than those
in the BMS  group (2.5 ± 0.61 mm vs. 2.7 ± 0.58 mm,  p = 0.036 and
16.2 ± 4.6 mm  vs. 11.5 ± 3.7 mm,  p < 0.001). As to PCI procedure,
a signiﬁcantly larger number of stents was  implanted (1.3 ± 0.49
vs. 1.2 ± 0.40, p = 0.010) and smaller size with longer stent were
used in the DES group than in the BMS  group (2.8 ± 0.30 mm
vs. 3.3 ± 0.45 mm,  p < 0.001 and 23.8 ± 12.4 mm  vs. 15.9 ± 6.0 mm,






61 (45) 60 (47) 0.806
43 (32) 16 (12) <0.001
32 (24) 53 (41) <0.001
74 (54) 40 (31) <0.001
0.66 ± 0.33 0.71 ± 0.42 0.232
2.5 ± 0.61 2.7 ± 0.58 0.036
72 ± 12 74 ± 13 0.260
16.2 ± 4.6 11.5 ± 3.7 <0.001
2.5 ± 0.42 2.8 ± 0.51 <0.001
2.8 ± 0.45 3.1 ± 0.50 <0.001
11 ± 6 10 ± 7 0.112
21.2 ± 6.1 14.8 ± 5.6 <0.001
16 (12) 15 (12) 1.000
1.3 ± 0.49 1.2 ± 0.40 0.010
2.8 ± 0.30 3.3 ± 0.45 <0.001
23.8 ± 12.4 15.9 ± 6.0 <0.001
15.5 ± 3.7 14.8 ± 3.3 0.129
126.7 ± 24.5 111.4 ± 17.2 <0.001
ge of Cardiology deﬁnition; DES, drug-eluting stent; BMS, bare-metal stent; QCA,
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Table  4
Univariate and multivariate logistic regression analyses for periprocedural myocardial injury.
Variable Univariate Multivariate
Odds ratio 95% Conﬁdence interval p Odds ratio 95% Conﬁdence interval p
Age 0.99 0.97–1.02 0.547
Male 0.65 0.33–1.25 0.195 0.69 0.34–1.43 0.320
Body  mass index 1.04 0.96–1.12 0.318
Hypertension 0.85 0.44–1.64 0.630 0.78–2.61 0.256
Diabetes 0.84 0.48–1.45 0.531 1.00–1.02 0.045
Current smoker 0.98 0.53–1.82 0.954
Multiple vessel disease 1.69 0.97–2.96 0.065 1.42 0.40–1.25 0.231
LDL-C  1.01 1.00–1.02 0.159 1.01
HDL-C 1.01 0.99–1.03 0.532 0.84–2.87 0.162
Hemoglobin A1c 0.91 0.70–1.20 0.517 0.56–1.60 0.843
High sensitivity 0.90–1.04 0.344
C-reactive protein 0.89 0.66–1.20 0.430
ACE-I and/or ARB 1.00 0.57–1.74 0.997 0.39–2.14 0.833
Calcium channel blockers 0.65 0.38–1.13 0.128 0.70 0.97–1.03 0.893
Beta-blockers 1.09 0.58–2.02 0.797
Nitrates 1.44 0.75–2.78 0.273 1.09–5.70 0.031
Complex lesion (type B2/Ca) 1.81 1.04–3.15 0.036 1.55
Reference vessel diameter 0.89 0.56–1.40 0.604 0.95
Lesion length 1.02 0.96–1.07 0.608 0.97
Direct stenting 1.66 0.75–3.67 0.211
Number of stent 1.23 0.68–2.21 0.501
Stent size 0.51 0.27–0.98 0.044 0.91
Total stent length 1.02 0.99–1.04 0.150 1.00
Maximum inﬂation pressure 1.02 0.95–1.12 0.546
Total balloon inﬂation time 1.00 0.99–1.01 0.817
DES  use 2.38 1.34–4.23 0.003 2.49


































llockers; DES, drug-eluting stent.
a Lesion type was classiﬁed according to American Heart Association/American C
n the DES group than in the BMS  group (126.7 ± 24.5 s vs.
11.4 ± 17.2 s, p < 0.001). No death, myocardial infarction, or repeat
evascularization was seen in enrolled patients during their hos-
italization. Using multivariate logistic regression analysis after
djustment for the confounding factors, low-density lipoprotein
holesterol levels and use of DES remained independent predictors
or PMI  (odds ratio 1.01, 95% CI 1.00–1.02, p = 0.045, and odds ratio
.49, 95% CI 1.09–5.70, p = 0.031, respectively) (Table 4). In our sub-
nalysis, among patients treated with DES, sirolimus-eluting stents
ere implanted in 69 (51%) patients and paclitaxel-eluting stents
n 67 (49%). No signiﬁcant difference was seen in the incidence of
MI  between the use of a sirolimus- and a paclitaxel-eluting stent
28% vs. 19%, p = 0.314).
iscussion
A major ﬁnding of this non-randomized study was  that
irolimus- and paclitaxel-eluting stent implantation signiﬁcantly
ncreased the incidence of PMI  after successful PCI compared to
MS  implantation. Recently, DES implantation has been one of
he standard treatments for AP patients. Use of a DES remark-
bly reduces the incidence of restenosis and the need for repeat
evascularization compared to that of BMS  [3–5]. Restenosis after
CI is reportedly associated with increased risk of death [2].  Thus,
reventing restenosis may  improve the clinical outcome includ-
ng a lower mortality rate. However, until now, use of DES has not
mproved mortality in patients with AP in spite of their notable sup-
ressive effect for neointimal hyperplasia compared to that of BMS
6–8]. Several mechanisms may  explain this discrepancy. Although
tent thrombosis which likely occurs after DES implantation is a
easonable explanation [17–20],  this matter has not been fully elu-
idated. In such situations, we hypothesized that DES implantation
ay  be associated with a higher incidence of PMI  and affect the
linical outcome after PCI. PMI  diagnosed by elevation in plasma
evels of cardiac enzyme, such as CK-MB and cardiac troponin even of Cardiology deﬁnition.
after successful PCI is a predictor of poor prognosis [9–12]. Ioannidis
et al. have demonstrated that CK-MB ratio 1–3, 3–5, and >5, carried
a relative risk of mortality; 1.5, 1.8, and 3.1, respectively [11]. Akker-
huis et al. also reported that in patients with CK-MB ratios of 0–1,
1–3, 3–5, 5–10, and >10, the risk of death was 1.3, 2.0, 2.3, 4.3, and
7.4%, respectively [12]. Therefore, our results might be one possible
reason why  DES cannot improve the mortality of patients despite
their evident risk reduction of restenosis compared to BMS.
The causes of PMI  are multifactorial and include patient, angio-
graphic, and procedural factors [21]. Of these procedural factors
are important [22]. More complex lesions require a more com-
plex procedure to predispose to PMI  [21]. In the present study,
patients treated with DES had worse metabolic proﬁles, more com-
plex lesions, and were treated with more complicated procedures
than those treated with BMS. However, even after adjustment
for these confounding factors, DES implantation remained an
independent predictor for PMI. Side branch occlusion and distal
embolization are considered as important causes of PMI. However,
in this study, we  excluded patients with major branch occlusion
or slow-ﬂow/no-reﬂow phenomenon. Microcirculatory plugging of
platelets and neutrophils caused by platelet activation, thrombo-
sis, and inﬂammation might be associated with PMI  [23]. Therefore,
microcirculatory injury due to minor side branch occlusion and/or
distal embolization which could not be detected by angiography
might be a possible mechanism of PMI. Microcirculatory vasospasm
introduced by exposure to vasoconstrictors is also considered as a
possible cause of PMI  [23]. In vitro experiments have suggested that
the ﬁrst generation DES may  decrease NO bioavailability, result-
ing in impaired endothelial-dependent vasorelaxation [24,25].  In a
clinical setting, impaired endothelial-dependent vasomotor func-
tion which is detected by paradoxical vasoconstriction via stimuli of
acetylcholine infusion, after the ﬁrst-generation DES implantation
is well documented [22–32].  In such a situation, it could be specu-
lated that microcirculatory vasospasm via hypersensitivity reaction
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he released drug might be possible mechanisms of our ﬁndings.
owever, this theory is just speculation, thus, further investiga-
ions providing insight into the potential mechanism of our results
re warranted.
In the present study, to detect PMI  perceptively, we  deﬁned PMI
s an increase in CK-MB greater than the ULN. However, when
e applied the deﬁnitions of it as an increase in CK-MB three or
ve times greater than the ULN, the association of high incidence
f PMI  with DES use disappeared. In our institution, both statins
nd thienopyridine drugs are prescribed to all patients undergo-
ng elective PCI to prevent PMI, if not contraindicated [33–36].  In
ddition to the relatively small sample size of this study, these
ight be reasons for aforementioned discrepancies and differ-
nces between our results and those of previous studies [3,4].
urthermore, this study was a non-randomized study. Therefore,
here was likely selection bias since DES might be used in patients
ho were generally considered as high-risk subjects for restenosis.
lthough multivariate analysis demonstrated that use of DES was
n independent predictor for PMI, we could not completely adjust
ll potential factors affecting PMI. For these reasons, our ﬁndings
hould be interpreted carefully. In addition, this study consisted of
atients treated with many types of coronary stents with various
esigns, limiting the generalization of our results.
In conclusion, our results demonstrated that the ﬁrst-generation
ES implantation was associated with a higher prevalence of PMI  in
table AP patients compared to BMS  implantation, when we deﬁned
MI as an increase in CK-MB greater than the ULN after the proce-
ure. Although this relationship depended on the deﬁnitions for
MI, they might be a possible reason why DES could not improve
ong-term mortality despite their promising effect for the preven-
ion of restenosis. To conﬁrm our speculations, clinical outcomes
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